Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 7/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | F2R | P25116 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9996647 | 0.88 | — | — | |
| SCHEMBL8989032 | 0.86 | NCF1 (0.48) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL24319800 | 0.84 | NCF1 (0.62) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL14661381 | 0.82 | NCF1 (0.45) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL1098836 | 0.80 | NCF1 (0.52) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL15721230 | 0.80 | NCF1 (0.58) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL245769 | 0.79 | NCF1 (0.56) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL772570 | 0.79 | — | — | |
| SCHEMBL11164665 | 0.79 | NCF1 (0.56) | NCF1ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL3948738 | 0.78 | GNAO1 (0.45) | GNAO1HRH3HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111362932-A | Isothiazole oxadiazole amide derivatives and preparation method and application thereof | 南开大学 | 2020-07-03 | — | — | CN | claimed |
| WO-2011033094-A1 | SCHEDULE OF ADMINISTRATION OF BENZAZOLE DERIVATIVES IN THE TREATMENT OF LEUKEMIAS | 4SC AG (DE) | 2011-03-24 | — | — | WO | claimed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | claimed |
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | claimed |
| CN-100354263-C | Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles | WYETH CORP (US) | 2007-12-12 | — | — | CN | claimed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1709007-A1 | N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS | Altana Pharma AG (DE) | 2006-10-11 | — | — | EP | claimed |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | AMGEN INC. | 2006-02-23 | — | — | US | claimed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | claimed |
| CN-1665787-A | Process for preparing 7-substituted-3-quinolines and 3-quinol-4-one carbonitriles | WYETH CORP (US) | 2005-09-07 | — | — | CN | claimed |
| EP-1499594-B1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH CORP (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2005070900-A1 | N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | WO | claimed |
| EP-1499594-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | Wyeth Holdings Corporation (US) | 2005-01-26 | — | — | EP | claimed |
| US-6780996-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION | 2004-08-24 | — | — | US | claimed |
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | WYETH HOLDINGS CORPORATION | 2003-11-13 | — | — | US | claimed |
| WO-2003093241-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH HOLDINGS CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| US-5294734-A | 1-phosphato-4-amino-pent-2-enoic acids and derivatives | CIBA-GEIGY CORP. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0420806-A1 | Phosphonic acids, process for preparation and use as an active pharmaceutical composition | CIBA-GEIGY AG (CH) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | RIPK1, RIPK3, RIPK4 | NCF1 1428/4885ACHE 4212/4885GNAI3 1014/4885 |
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | MAP4K2, MAP3K7, MAP4K1 | NCF1 1471/4885ACHE 3349/4885GNAI3 502/4885 |
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | NCF1 1323/4885ACHE 3857/4885GNAI3 807/4885 |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | EDNRA, PTGIS, EDNRB | NCF1 1793/4885ACHE 1560/4885GNAI3 410/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | NCF1 2240/4885ACHE 2453/4885GNAI3 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.